Studies in Human Malaria

XXXII. The Protective and Therapeutic Effects of Pyrimethamine (Daraprim) Against Chesson Strain Vivax Malaria

G. Robert CoatneyLaboratory of Tropical Diseases, National Microbiological Institute, National Institutes of Health, Bethesda 14, Maryland

Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Close
,
A. V. MyattLaboratory of Tropical Diseases, National Microbiological Institute, National Institutes of Health, Bethesda 14, Maryland

Search for other papers by A. V. Myatt in
Current site
Google Scholar
PubMed
Close
,
Thomas HernandezLaboratory of Tropical Diseases, National Microbiological Institute, National Institutes of Health, Bethesda 14, Maryland

Search for other papers by Thomas Hernandez in
Current site
Google Scholar
PubMed
Close
,
G. M. JeffereyLaboratory of Tropical Diseases, National Microbiological Institute, National Institutes of Health, Bethesda 14, Maryland

Search for other papers by G. M. Jefferey in
Current site
Google Scholar
PubMed
Close
, and
W. Clark CooperLaboratory of Tropical Diseases, National Microbiological Institute, National Institutes of Health, Bethesda 14, Maryland

Search for other papers by W. Clark Cooper in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary

This study was undertaken to evaluate the protective and therapeutic efficacy of pyrimethamine (Daraprim) against Chesson strain Plasmodium vivax in human volunteers. The drug was highly effective as a suppressive agent, 0.8 to 25 mg. gave complete protection during drug administration; it was less efficient when used for therapy of acute attacks. Pyrimethamine does not appear to be a true causal prophylactic although prolonged delays before patent parasitemia suggested some deleterious effect against early tissue stages of the parasite. Weekly administration of the drug for 8 or more weeks resulted in suppressive cure of many infections. Probably the greatest usefulness of the drug will be for routine suppression.

Save